| 英文名称 | 中文名称 | CAS |
|---|---|---|
| UNC 0631 | UNC 0631 | 1320288-19-4 |
| TMS - Trans-2,3',4,5'-tetramethoxystilbene | 2,3',4,5'-四甲氧基二苯乙烯 | 24144-92-1 |
| Zardaverine | 扎达维林 | 101975-10-4 |
| Voriconazole - Vfend | UK 109496 | 伏立康唑 | 137234-62-9 |
| UK 383367 | UK 383367 | 348622-88-8 |
| TMP 195 - TFMO 2 | TMP195游离态 | 1314891-22-9 |
| Tucidinostat - Chidamide | HBI-8000 | CS 055 | Epidaza | 西达本胺 | 1616493-44-7 |
| VER 155008 | VER 155008 | 1134156-31-2 |
| UNC 0224 | UNC 0224 | 1197196-48-7 |
| UNC 0638 | UNC0638 | 1255580-76-7 |
| Trelagliptin succinate - SYR 111472 succinate | SYR 472 | 琥珀酸曲格列汀 | 1029877-94-8 |
| TWS 119 | TWS119 | 601514-19-6 |
| Trovafloxacin mesylate - CP 99219 mesylate | 曲伐沙星甲磺酸盐 | 147059-75-4 |
| XMD 8-92 trifluoroacetate | 2-[[2-乙氧基-4-(4-羟基-1-哌啶基)苯基]氨基]-5,11-二氢-5,11-二甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮 | 1234480-50-2 |
| Tubastatin A hydrochloride | Tubastatin A盐酸盐 | 1310693-92-5 |
| XL 019 | XL019 | 945755-56-6 |
| XL 388 | [7-(6-氨基-3-吡啶基)-2,3-二氢-1,4-苯并氧氮杂卓-4(5H)-基][3-氟-2-甲基-4-(甲基磺酰基)苯基]-甲酮 | 1251156-08-7 |
| WH-4-023 | 2,6-DIMETHYLPHENYL 2,4-DIMETHOXYPHENYL(2-(4-(4-METHYLPIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDIN-4-YL)CARBAMATE | 837422-57-8 |
| YS 49 | 1,2,3,4-四氢-1-(1-萘基甲基)-6,7-异喹啉二醇氢溴酸盐 | 132836-42-1 |
| UPF 1069 | 5-(2-氧代-2-苯基乙氧基)-1(2H)-异喹啉酮 | 1048371-03-4 |
| TTP 22 | TTP 22 | 329907-28-0 |
| VE 822 | VE-822 | 1232416-25-9 |
| UPF 648 | 213400-34-1 | 213400-34-1 |
| ZL006 | 化合物ZL006 | 1181226-02-7 |
| URB602 | 3-(环已氧羰基胺基)联苯 | 565460-15-3 |
| Y 29794 tosylate | Y-29794 tosylate | 143984-17-2 |
| Zebularine | 2-嘧啶酮-B-核甙 | 3690-10-6 |
| Valdecoxib - SC 65872 | Bextra | 代他考昔 | 181695-72-7 |
| U 0126 - U 126 | 1,4-二氨基-2,3-二氰基-1,4-双(邻氨基苯巯基)丁二烯 | 109511-58-2 |
| VX 680 - MK 0457 | Tozasertib | 陶扎色替 | 639089-54-6 |
| Torin 2 | 9-(6-氨基-3-吡啶基)-1-[3-(三氟甲基)苯基]苯并[H]-1,6-萘啶-2(1H)-酮 | 1223001-51-1 |
| Torin 1 | 1-[4-[4-(1-氧代丙基)-1-哌嗪基]-3-(三氟甲基)苯基]-9-(3-喹啉基)苯并[H]-1,6-萘啶-2(1H)-酮 | 1222998-36-8 |
| VE 821 | 3-氨基-6-[4-(甲基磺酰基)苯基]-N-苯基-2-吡嗪甲酰胺 | 1232410-49-9 |
| UNC 0646 | N-(1-环己基-4-哌啶基)-2-[六氢-4-异丙基-1H-1,4-二氮杂卓-1-基]-6-甲氧基-7-[3-(1-哌啶基)丙氧基]-4-喹唑啉胺 | 1320288-17-2 |
| YMU1 | Ethyl 4-(2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl)piperazine-1-carboxylate | 902589-96-2 |
| UF 010 | UF 010 | 537672-41-6 |
| TPI-1 | TPI1;TPI 1 | 79756-69-7 |
| ZT-12-037-01 | ZT-12-037-01 | 2328073-61-4 |
| U 73122 | 1-[6-[((17Β)-3-雌酮-1,3,5[10]-三烯-17-基)氨基]乙基]-1H-吡咯-2,5-二酮 | 112648-68-7 |
| Y 700 - Piraxostat | 化合物 T33676 | 206884-98-2 |
| Wnt-C59 - C59 | PORCN酶活性和WNT抑制剂(WNT-C59) | 1243243-89-1 |
| USP7-USP47 inhibitor - USP7/47 inhibitor compound 14 | 4-氰基-5-[(3,5-二氯-4-吡啶基)硫基]-N-[4-(甲基磺酰基)苯基]-2-噻吩甲酰胺 | 1247825-37-1 |
| TM 5441 | CS-2510 | 1190221-43-2 |
| Vildagliptin - NVP-LAF 237 | 维格列汀 | 274901-16-5 |
| YK 4-279 | YK 4-279 | 1037184-44-3 |
| Vidofludimus - 4SC-101 | SC 12267 | 维多氟拉迪莫 | 717824-30-1 |
| VH298 | VH298 | 2097381-85-4 |
| TMI 005 - Apratastat | N-羟基-4-[[4-[(4-羟基-2-丁炔基)氧基]苯基]磺酰基]-2,2-二甲基-3-硫代吗啉甲酰胺 | 287405-51-0 |
| XAV 939 - NVP-XAV 939 | 3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-噻喃并[4,3-D]嘧啶-4-酮 | 284028-89-3 |
| UK 356618 - PF 03890101 | UK 356618 | 230961-08-7 |
| Y 27632 dihydrochloride | Y27632 (HYDROCHLORIDE) | 129830-38-2 |
| WP 1130 - Degrasyn | WP1130 | 856243-80-6 |
| WP 1066 | (2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺 | 857064-38-1 |
| ZCL 278 | ZCL278 | 587841-73-4 |
| ZLN 024 | 2-[[2-(2-溴-4-甲基苯氧基)乙基]硫基]嘧啶 | 723249-01-2 |
| YUKA1 | YUKA1 | 708991-09-7 |
| VX 745 | VX-745 | 209410-46-8 |
| Toloxatone - MD 69276 | 涛洛西酮 | 29218-27-7 |
| ZM 447439 | ZM 447439 | 331771-20-1 |
| Tofacitinib citrate - CP 690550-10 | 枸橼酸托法替尼 | 540737-29-9 |
| XL 413 hydrochloride - BMS 863233 hydrochloride | XL413 (BMS-863233) | 1169562-71-3 |
| WZ 4003 | WZ4003 | 1214265-58-3 |
| UNC 0379 | UNC0379 | 1620401-82-2 |
| XMD 8-87 | 5,11-二氢-2-((2-甲氧基-4-(4-甲基-1-哌嗪基)苯基)氨基)-11-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮 | 1234480-46-6 |
| XL PI3K/mTOR inhibitor | XL PI3K/mTOR inhibitor | 934529-30-3 |
联系方式
电话：703 - 9861
邮箱：info@axonmedchem.com
网址： http://www.axonmedchem.com
产品总数： 763
CB指数：58
国籍：美国
